Loading...
•
Sep 30, 2021
Guardant Health Q3 2021 Earnings Report
Guardant Health's revenue increased by 27% year-over-year, driven by growth in clinical and biopharma test volumes.
Key Takeaways
Guardant Health reported a 27% increase in revenue for the third quarter of 2021, reaching $94.8 million. The company saw significant growth in clinical and biopharma test volumes, despite the continued impact of COVID-19. However, the net loss also increased to $107.5 million, or $1.06 per share.
Revenue reached $94.8 million, a 27% increase compared to the third quarter of 2020.
Clinical tests increased by 35% year-over-year, with 22,806 tests reported.
Biopharmaceutical tests increased by 58% year-over-year, with 4,839 tests reported.
ORACLE study initiated to evaluate Guardant Reveal™ for predicting recurrence across eleven early-stage cancers.
Guardant Health
Guardant Health
Guardant Health Revenue by Segment
Revenue by Segment
Oncology Revenue
CapyFin.com Forward Guidance
Guardant Health expects full year 2021 revenue to be in the range of $360 million to $370 million, representing 26% to 29% growth over full year 2020.
Positive Outlook
- Full year 2021 revenue expected to be in the range of $360 million to $370 million.
- Revenue growth of 26% to 29% expected over full year 2020.
- Expansion of product portfolio with focus on early-stage cancer detection.
- Continued progress in developing blood-based cancer screening tests.
- Focus on improving patient clinical outcomes and lowering healthcare costs.